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a  b  s  t  r  a  c  t
Mother-to-child transmission (MTCT) of human immunodeﬁciency virus (HIV) infection
remains an important cause of new HIV infections worldwide, especially in low and middle-
resource limited countries. Safety data from studies involving pregnant women and prenatal
antiretroviral (ARV) exposure are still needed once these studies are often small and with
a  limited duration to assess adverse drug reactions (ADR). The aim of this study was to
estimate the incidence of ADR related to the use of antiretroviral therapy (ART) in pregnant
women in two referral centers in Rio de Janeiro State. A prospective study was carried out
from February 2005 to May 2006. Women were classiﬁed according to their ART status during
pregnancy diagnosis: ARV-experienced (ARTexp) or ARV-naïve (ARTn). Two hundred fourteen
HIV-infected pregnant women were included: 36 ARTexp and 178 ARTn. ARTexp women have
not  experienced ADR. Among ARTn, 20.2% presented ADR. Incidence rate of ADR was 70.8
per  1000 person-months and the most common ADRs observed were: gastrointestinal (belly
or  abdominal cramps, diarrhea, nausea and vomit) in 16.3%, cutaneous (pruritus and rash)
in  6.2%, anemia (2.2%) and hepatitis (1.7%). The frequency of obstetrical complications, pre-
term delivery, low birth weight and birth abnormalities was low in this population. ADRsranged from mild to moderate intensity, none of them being potentially fatal. Only in a few
cases it was necessary to discontinue ART. In conclusion, the high effectiveness of ARV for
HIV  prevention of MTCT (PMTCT) overcomes the risk of ADR.∗ Corresponding author at: Av. Brasil, 4365, Manguinhos, 21045-900, Rio
E-mail address: marilia.santini@ipec.ﬁocruz.br (M. Santini-Oliveira)
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ntroduction
other-to-child transmission (MTCT) of human immunode-
ciency virus (HIV) infection remains an important cause of
ew HIV infections worldwide. In 2011, the global impact
f HIV on children was enormous, with an estimated
30,000 children becoming infected in low and middle-income
ountries, mostly through MTCT during pregnancy, labor and
elivery or by breastfeeding.1 Great scientiﬁc successes have
een achieved over the past decade in HIV prevention of MTCT
PMTCT) with the development of effective antiretroviral (ARV)
nterventions during pregnancy, labor/delivery, and neonatal
rophylaxis, as well as with elective cesarean delivery and
voidance of breast feeding.2–4 Antiretroviral prophylaxis pre-
ents HIV acquisition for as many  as 409,000 children in low-
nd middle-income countries.1 Nowadays, PMTCT of HIV pro-
rams are implemented in many  countries across the world,
aking in utero ARV exposure and its potential consequences a
lobal issue. Despite the clear success of PMTCT programs and
he fact that the vast majority of infants born to HIV-infected
others can be protected from acquisition of infection, safety
ata from studies involving pregnant women and prenatal
RV exposure are still needed once human perinatal ARV stud-
es are often small and of short duration to assess adverse drug
eactions (ADR).
The aim of this study is to describe the incidence of ADRs
elated to the use of ARV in pregnant women in two referral
enters for PMTCT care and research in Rio de Janeiro State,
razil.
aterials  and  methods
tudy  design
his prospective study was conducted at Hospital Federal
os Servidores do Estado (HFSE) and Hospital Geral de Nova
guac¸u (HGNI), both located at Rio de Janeiro State, Brazil from
ebruary 2005 to May 2006. This study was approved by the
PEC-FIOCRUZ institutional review board. Participant eligibil-
ty criteria were: (1) pregnant women older than 18 years; (2)
estacional age between 14 and 30 weeks; (3) HIV diagnosis
onﬁrmed by serology or HIV RNA viral load; (4) use of at
east one dose of any ARV during pregnancy; (5) having had
t least one medical appointment after the pregnancy diagno-
is.
Women were classiﬁed according to antiretroviral therapy
ART) status at pregnancy diagnosis: ARV experienced (ART-
xp) or ARV-naïve (ARTn); these two groups were analyzed
eparately. Women were followed up from pregnancy diagno-
is until delivery.
Data were collected by two trained health professionals
one physician and one pharmacist) on the study procedures
nd deﬁnitions. The medical records of all patients included
n the study were reviewed in a weekly basis until the end of
he follow-up period, in order to update clinical information,
ocusing on ADR. Standardized forms to collect demographic,
linical, ART and ADR data were designed and piloted before
tudy initiation.4;1 8(4):372–378 373
Study  deﬁnitions
Demographic and clinical characteristics at baseline included:
age (years), race (white or non-white), number of previ-
ous pregnancies (0, 1–2, ≥3), number of living children
(0, 1–2, ≥3), HIV exposure category (sexual, injecting drug
use, or unknown), previous AIDS-deﬁning illness, time until
HIV diagnosis (months), nadir CD4+ lymphocyte T-cells<
or ≥200 cels/L, baseline CD4+ lymphocyte T-cell, high-
est and lowest CD4+ lymphocyte T-cells during pregnancy,
baseline HIV RNA viral load (copies/mL), HIV RNA viral
load > 1000 copies/mL during pregnancy, gestational age at
study entry, route of delivery (vaginal route or cesarean sec-
tion), pregnancy outcome (term birth, preterm birth and
abortion), ART use during pregnancy (weeks), ARV modiﬁca-
tion (at least one ARV of the regimen modiﬁed) and type of
ART: non-nucleoside reverse transcriptase inhibitor (NNRTI),
protease inhibitors (PI), NNRTI + PI, or nucleoside reverse
transcriptase inhibitor (NRTI) only.
ADR related to ARVs were classiﬁed according to infor-
mation collected from the medical charts, and were grouped
as follows: gastrointestinal (GI) (diarrhea, vomiting, nausea,
belly cramps), cutaneous (exanthema, pruritus), hematologic
(anemia, neutropenia, and thrombocytopenia), hepatic, and
constitutional symptoms (asthenia).
The most frequent ADR related to ARVs (gastrintestinal,
cutaneous, hematologic and hepatic) were graded according to
the DAIDS Table for Grading the Severity of Pediatric Adverse
Events5 on intensity (mild, moderate and severe). Causality
between ADR and ARV was assessed according to6 and deﬁned
as deﬁnitely, probably and possibly ARV-related. Other carac-
theristics related to the ADR were also assessed: serious (yes
or not), outcome (resolved or ongoing), type of ART (NNRTI and
PI), time to ADR onset (weeks), and ADR duration (weeks).
Statistical  analysis
Incidence rate and conﬁdence interval for each ADR was esti-
mated by Poisson model and reported it as the number of
occurrences per 1000 person-months. The statistical software
R, version 2.14.1 (www.r-project.org) was used for all statistical
analyses.
Results
A total of 214 HIV-infected pregnant women were included
in this study; at the time of pregnancy diagnosis 36 were
ART-experienced (ARTexp) and 178 ARV-naïve (ARTn). Demo-
graphic, clinical and ART characteristics for both groups are
presented in Table 1.
Women  under  ART  use  at  pregnancy  diagnosis  (ART  exp)
For the ARTexp group, median time from ART initiation until
labor was 23.7 months (IQR6.4–66.4).Eighteen women (50%) were using an Efavirenz (EFV) based
regimen when they became pregnant and have been switched
to the following ARVs in order to avoid teratogenic effects:
lopinavir/ritonavir (LPV/r) in three cases, nevirapine (NVP)
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Table 1 – Demographic, clinical and ART characteristics for 214 pregnant women included in this study from HGNI and
HFSE, Rio de Janeiro, Brazil.
Variable ARTexp women (n = 36, 16.8%) ARTn women (n = 178, 83.2%)
Age (years), Median (IQR) 30.7 (26.8–34.8) 27.6 (23.3–31.9)
Race, n (%)
White 16 (44.4) 58 (32.5)
Non-white 20 (55.6) 113 (63.5)
Not declared – 7 (4.0)
Previous pregnancies, n (%)
1–2 16  (44.4) 91  (51.1)
≥3 12 (33.3) 62  (34.8)
Living children, n (%)a
1–2 13 (36.1) 95 (53.4)
>3 9 (25.0) 40 (22.5)
HIV exposure category, n (%)
Sexual 31 (88.1) 166 (93.8)
Intravenous drug use 0 (0.0) 2 (1.1)
Unknown 5 (11.9) 10 (5.1)
Previous AIDS-deﬁning illness, n (%) 5 (13.9) 1 (0.6)
Time until HIV diagnosis (months), median (IQR) 36 (21.2–55.5) 7.3 (1.2–19.3)
CD4 (cells/mm3) data
Nadir ≥ 200 cells/L, n (%) 22  (61.1) 159  (89.3)
Baseline, median (IQR) 351.5 (193.8–466.0) 422.5 (297.8–569.8)
Higher value during pregnancy, median (IQR) 446.0 (288.0–561.0) 520.0 (379.0–681.0)
Lower value during pregnancy, median (IQR) 338.0 (190.5–342.9) 404.0 (292.0–551.0)
Viral load (copies/mL)
Baseline, median (IQR) 400.0 (400.0–2900.0) 4950.0 (640.0–29000.0)
Viral load > 1000 copies/mL during pregnancy, n (%) 10 (28.6) 28 (17.9)
Gestational age on baseline, mean (±SE) 15.7 (1.0) 21.1 (0.6)
Route of delivery, n (%)
Vaginal route 16 (44.4) 61 (34.3)
Cesarean section 20 (55.6) 117 (65.7)
Pregnancy outcome, n (%)
Term birth 30 (83.4) 163 (91.5)
Preterm birth 4 (11.1) 14 (7.8)
Abortion 2 (5.5) 1 (0.7)
ART-based regimen, n (%)
NNRTI 16 (44.4) 73 (41.1)
PI 19 (52.8) 103 (57.8)
PI + NNRTI 1 (2.8) –
NRTI – 2 (1.1)
ART use during pregnancy (weeks), median (IQR) N/A 16.1 (10.0–22.0)
ARV modiﬁcation, n (%) 24 (66.7%) 10 (5.6)
d erroaExcluding current pregnancy; IQR = interquartile range; SE = standar
in eleven cases, and nelﬁnavir (NFV) in four cases. Mean
gestational age at the time of EFV discontinuation was 16
weeks (SE + 0.8). No obstetric complications during labor were
observed and no infants were born with low birth weight or
had congenital malformations diagnosed. EFV use was signif-
icantly associated with neither abortion nor premature birth
(p = 0.825).
After the EFV switch, 16 women were using an NNRTI-
based regimen, all of them were receiving Nevirapine (NVP);
19 women were using a PI-based regimen, nine with LPV/r,
eight with NFV, and one with saquinavir plus ritonavir (SQV/r);
one woman was taking an NNRTI + PI containing regimen
(LPV/r + NVP). Mean time of exposure to the new ART after EFV
switch was 29.8 weeks (SE + 1.2).r.
Six women modiﬁed at least one ARV during gestation due
to virological failure, three were in use of NVP (switched to
NFV) and three were taking NFV (switched to LPV/r). Mean time
of exposure to the new ART after virological failure was 4.2
weeks (SE + 0.4).
Ten adverse medical events not related to ART were
observed: hypertension (4), hepatitis C (HCV) co-infection
(1), syphilis (1), ischemic heart disease (1), genital warts (1),
pyelonephritis (1), and seizure in a patient with previous
epilepsy diagnosis (1). Twenty-six women (77.8%) had no com-
plication whatsover during prenatal period.Overall, only one obstetric complication was veriﬁed, a fetal
distress caused by preeclampsia. Only one child had low birth
weight (2420 g).


















































Table 2 – Frequency and incidence rate of ADR in 178
ARTn women from HGI and HFSE, Rio de Janeiro, Brazil.
ADR Events (%) Incidence (per 1000
person-months)
Gastrointestinal (GI) 29 (16.3) 42.8
Diarrhea 17 (9.5) 25.1
Vomiting 6 (3.4) 8.9
Nausea 5 (2.8) 7.4
Belly or abdominal cramps 1 (0.6) 1.5
Cutaneous 11 (6.2) 16.2
Exanthema 8 (4.5) 11.8
Itching 3 (1.7) 4.4
Hematologic 4 (2.2) 5.9
Anemia 4 (2.2) 5.9
Neutropenia 0 (0.0) 0.0
Thrombocytopenia 0 (0.0) 0.0
Hepatic 3 (1.7) 4.4
Constitutional: asthenia 1 (0.6) 1.5b r a z j i n f e c t d i s .
Six undesirable pregnancy outcomes occured: two induced
iscarriage and four premature births. All pregnant women
ho  gave birth prematurely had a nadir CD4+ T lympho-
yte > 200 cells/L, two were on NVP and two on PIs. The rate
f preterm birth was not different in pregnant women on PI or
n NNRTI (p = 1.00). Mean baseline CD4+ T lymphocyte count
as 563 cells/L (IQR 377.25–749.75) and 291.5 cells/mm3 (IQR
88.5–291.5) in women who had premature birth and in those
ho  gave birth at term, respectively.
No ADR during pregnancy were observed for all 36 women.
RV-naïve  women  at  pregnancy  diagnosis  (ARTn)
 total of 178 ARTn patients were included in this study. NVP
as prescribed to all 73 patients (41.0%) who were started
n NNRTI-based regimen. For PI-based regimens, 93, eight,
nd two pregnant women received NFV, LPV/r, and atazanavir
ATV), respectively. Two patients received NRTI-only based reg-
men, one received zidovudine (ZDV) monotherapy and one
eceived a combination of ZDV, lamivudine (3TC) and abacavir
ABC). Eleven women (6.2%) modiﬁed at least one ARV during
regnancy, and all modiﬁcations were toxicity-driven.
Twenty adverse events (AE) not related to ART occurred
mong 10 women: hypertension (3), genital herpes (3), syphilis
3), oral candidiasis (2), upper respiratory tract infection (1),
onjunctivitis (1), gestational diabetes diagnosed before ART
nitiation (1), facial cellulitis (1), herpes zoster (1), pyelonephri-
is (1), sinusitis (1), bacterial vaginosis (1) and scabies (1). Six
omen (3.4%) had obstetric complications during pregnancy
nd labor: ruptured membranes (3), perinatal asphyxia and
terine atony leading to hysterectomy (1), failure to progress in
abor (1) and placental abruption (1). Only one child was born
ith low birth weight (2120 g). A hundred sixty-two women
91.0%) had no complications during prenatal period.
No statistically signiﬁcant difference in the rate of preterm
elivery in pregnant women according to ART-based regimen
as observed. No difference was found in preterm delivery
ccording to the ART regimen received.
Two children (1.1%) were born with congenital malforma-
ions diagnosed at birth, both with hemangioma, one on the
ace and one on chest, and these were not attributed to the
RV exposure.
DR  incidence  on  ARTn
mong those women who  developed ADR, mean ART expo-
ure was 16.3 weeks. The frequency and incidence of ADR
mong the 178 pregnant women enrolled as ARV-naïve are
epicted in Table 2. Thirty-six (20.2%) women developed 48
vents classiﬁed as ADR. Overall ADR frequency was 27%
48/178) and overall ADR incidence was 70.8 episodes per 1000
erson-months. Twenty-six, eight and two women experi-
nced one, two or three ADR, respectively. No potential fatal
DR was reported.
ADR intensity, relationship to ARV, evolution, duration
nd outcome on women enrolled as ARV-naïve are shown in
able 3.
Eleven women (6.2%) permanently discontinued at least
ne ARV due to the following ADR: moderate anemia related
o ZDV (1); diarrhea related to NFV (one moderate and oneTotal 48 (27.0) 70.8
severe); moderate hepatitis (1) and rash (7) related to NVP.
ZDV was replaced by stavudine (d4T), NFV by NVP and vice
versa. Among women starting ART with NVP, 9.6% (7/73) had
to permanently discontinue it.
GI events were the most frequent ADR observed and
most of them were observed one week after ART initiation.
Twenty-four women developed 29 GI ADR episodes (16.3%),
including diarrhea (9.5%), vomiting (3.4%), nausea (2.8%) and
belly or abdominal cramps (0.6%), with an overall incidence
of 42.8 episodes per 1000 person-months. These women
were more  frequently having a comorbidity during pregnancy
(p = 0.034), used PI-based regimen (p = 0.016), and were in a
more advanced gestational age at prenatal care initiation
(p = 0.014). Mild GI ADR was observed in 89.6% and one woman
had a serious ADR. Almost half of these events (44%) were
resolved without interrupting ART and in most cases they per-
sisted until labor. Almost all GI ADR (96.5%) occurred in women
using a PI-based regimen and only two women had to discon-
tinue their ARV regimen. All episodes of diarrhea were related
to NFV (18.3%).
Cutaneous ADR occurred in 6.2% women, including pru-
ritus (3; 1.7%) and exanthema (8; 4.5%), representing an
incidence of 16.2 episodes per 1000 person-months. There
were three cases of mild pruritus, which were resolved with-
out ART discontinuation. These women were using ATV (1)
and NVP (2) in combination with ZDV/3TC. Most cases of rash
ranged from moderate to severe (87.5%), but none of them
were classiﬁed as serious. The only case of mild intensity
was resolved without ART discontinuation. All cases of rash
occurred in pregnant women using a NVP-based regimen, with
an overall frequency of 10.9%. Cases of rash were identiﬁed
earlier than a week after ART initiation and rapidly improved
after NVP discontinuation.
Anemia occurred in four women (2.2%), representing
an incidence of 5.9 episodes per 1000 person months. No
other hematological ADR (neutropenia or thrombocytopenia)
occurred in our study population. All women who  had anemia
were using ZDV/3TC, two of them in combination with NVP,
one with LPV/r, and one with NFV. Anemia occurred for a mean
time of 2.3 weeks and it was diagnosed at a mean time of 2.2
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Table 3 – ADR, intensity, causality with ARV, evolution, duration and outcome in 178 ARTn women from HGNI and HFSE,
Rio de Janeiro, Brazil.
Variable Gastrintestinal (n = 29) Cutaneous (n = 11) Hematologic (n = 4) Hepatic (n = 3)
Intensity
Mild 26 (89.6) 4 (36.4) 2 (50.0) 2 (66.7)
Moderate 2 (6.9) 5 (45.5) 2 (50.0) 1 (33.3)
Severe 1 (3.5) 2 (18.2) 0 (0.0) 0 (0.0)
Causality
Deﬁnitely ARV-related 18 (62.1) 5 (45.5) 1  (25.0) 1  (33.3)
Probably ARV-related 6 (20.7) 6 (54.5) 3  (75.0) 2  (66.7)
Possibly ARV-related 5 (17.2) 0 (0.0) 0  (0.0) 0 (0.0)
Seriousness 0 (0.0) 0 (0.0) 1 (25.0) 0 (0.0)
Drug discontinuation 2 (6.9) 7 (63.6) 1 (25.0) 1 (33.3)
Outcome
Resolved 13 (44.8) 11 (100.0) 1 (25.0) 1 (33.3)
Ongoing 16 (55.2) 0 (0.0) 3 (75.0) 2 (66.7)
Type of ART
NNRTI 1 (3.5) 10 (90.9) 2 (50.0) 2 (66.7)
PI 28 (96.5) 1 (9.1) 2 (50.0) 1 (33.3)
Time to ADR onset (weeks), median (IQR) 0.3 (0.0–0.7) 0.5 (0.3–0.8) 2.1 (1.1–3.2) 0.6 (0.6–0.8)
ADR duration (weeks), median (IQR) 2.1 (1.4–3.6) 0.6 (0.2–0.7) 1.3 (0.7–2.9) 5.4 (3.1–5.7)IQR = interquartile range.
weeks after ART initiation. Almost all episodes of anemia were
mild to moderate. One case which required hospitalization
and blood transfusion was classiﬁed as serious, being resolved
after ZDV discontinuation in all cases. Anemia persisted until
delivery and only one woman had ART interrupted.
Three women (1.7%) had hepatitis, representing an inci-
dence of 4.4 episodes per 1000 person-months. Hepatitis
occurred 0.7 weeks after ART initiation and lasted for 4.1
weeks. All cases were mild or moderate and none of them
evolved to a severe outcome. Two women were using an NVP-
based regimen (overall frequency 2.7%) and one in a NFV-based
regimen, both combined with ZDC/3TC. NVP was permanently
discontinued in one woman. The other two cases of hepatitis
were mild and persisted until delivery.
One case (0.6%) of asthenia was observed in a woman in use
of ZDV + 3TC + NFV, representing an incidence of 1.5 episode
per 1000 person-months. This event started one week after
ARV onset and persisted until delivery.
Discussion
Our study provides important information on ARV safety pro-
ﬁle during pregnancy from two referral centers for PMCTC in
a middle income country where MCTC is still common. The
frequency of ADR related to ARVs in HIV-infected pregnant
women varies from 5% to 78%, depending on the geographic
region, social status, degree of immunodeﬁciency and length
of exposure to ART. Moreover, a favorable outcome is usually
observed, with no ARV interruption and without signiﬁcant or
permanent damage to pregnant women and their offspring,
which is consistent to our ﬁndings.7–10None of the ARTexp women developed ARV related ADR.
These women were receiving ART for over three years. Accord-
ing to the literature, the majority of clinically signiﬁcant ADR is
observed in the ﬁrst months of ART.11–13 ARTexp women whochanged any ARV during the study (EFV switch or virological
failure) received a new ARV from the same class (NNRTI or PI),
which may have reduced the possibility of ADR  related to class
switch, such as hypersensitivity reactions and GI intolerance.
In our study, discontinuation of NVP due to ADR was
more  frequently observed than in a recently published meta-
analysis including 20 studies and 3582 pregnant women.14
This could be attributed to high mean baseline CD4+ T lym-
phocyte cell count observed in our study sample, which is
associated to an increased risk of adverse events.14,15 In a
Canadian study, continuous NVP use in pregnancy resulted in
a relatively higher rate of toxicity when compared to women
not receiving NVP, and all cases occurred in women exposed to
NVP for the ﬁrst time during pregnancy.16 This could explain
the lack of toxicity in ARTexp women in our study.
The frequency of liver toxicity among pregnant women
starting a NVP-based regimen (2.7%) was similar to the low-
est rates reported in literature.14,17,18 The average CD4+ T
lymphocyte count in our cohort was 457.7 cells/L and CD4+
T lymphocyte counts above 250 cells/L is considered a risk
factor for hepatotoxicity.15 This may also explain the above
mentioned higher frequency of discontinuation of NVP due to
ADR.14 The frequency of hepatitis among women using NFV
(1%) was similar to that observed in controlled clinical trials
in adults using this ARV (2%).19,20
All ARTexp women were using ZDV for more  than three
years before pregnancy, and anemia occurs more  frequently
in the ﬁrst 12 weeks of ZDV use.21–23 Among ARTn women,
anemia related to ZDV was observed in 2.2%, which was
lower than that reported in the literature for HIV-infected
adults24 and comparable to rates reported among pregnant
women.9,25,26 Previous studies with pregnant women showed
that anemia is generally mild to moderate, rarely leading
to ARV discontinuation or interfering signiﬁcantly in the
health of the pregnant women, which is consistent with our
ﬁndings.9
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The frequency of GI ADR observed is consistent with the lit-
rature reports as abdominal or belly cramps, diarrhea, nausea
nd vomiting are well-known side-effects of PIs. Previous clini-
al trials with HIV-infected adults on NFV have shown diarrhea
n 20% of the patients and nausea and vomiting in 7%. Time
etween ART initiation and the onset of these side-effects is
enerally less than one week, with events ranging from mild to
oderate in most cases, persisting for long periods in almost
alf of the individuals.19,20,27
The observed frequency and clinical course of rashes
pisodes were similar to those reported in clinical trials
nd observational studies including HIV-infected adults,28,29
nd, more  speciﬁcally, to studies of HIV-pregnant women on
VP.14,15,18,30
No teratogenic effect was observed in any of the 17 infants
xposed to EFV during the ﬁrst trimester of pregnancy, which
s compatible to previous reports.31,32 The frequency of con-
enital malformations in this study (1.1%) was similar to that
bserved in a study conducted in Europe (1.5%),32 but lower
han that observed in a recent study from an Italian ARV cohort
3.2%).33–35 No data on the frequency of congenital malforma-
ions in the general population of infants at birth are available
n Brazil. Therefore, one can compare the rate of congenital
alformations encountered in this study with the rate in the
eneral population. However, since children were evaluated
nly at delivery this could have underestimated the rate in
ur study.
Frequency of other medical events was very low, and they
eem to be more  related to HIV-infection immunodeﬁciency
han to ART use during pregnancy.
In conclusion, the overall incidence of ADR was low in
omen exposed to ARV during PMTCT. None of the ADR
bserved were unexpected and in most cases they were mild
o moderate, with no fatal outcome. Discontinuation or sus-
ension of ARV was rare. The high effectiveness of ART for
MTCT overcomes the risks of adverse drug reactions.
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